A new category of immunotherapies called checkpoint inhibitors that has been highly effective against many different cancers appears safe to use in patients with both advanced malignancies and HIV, a population excluded from earlier trials of such therapies, according to an early-phase trial. Pembrolizumab belongs to a type of immunotherapy that blocks a braking system cancers use to tamp down the immune response.